Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

by Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani, Pier Luigi Canonico
Published 2018-11-01

[Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations in Italy]

by Andrea Belisari, Sergio Iannazzo, Giuseppe Di Pasquale, Claudio Fresco, Lorenzo Giovanni Mantovani, Maria Pia Ruggeri, Danilo Toni, Raffaele Landolfi
Published 2016-06-01

Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model

by Lorenzo Pradelli, Sara Villa, Giancarlo Castaman
Published 2018-01-01

Treatment cost of metastatic colon cancer in Turkey

by Guvenc Kockaya, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz, Saim Kerman
Published 2013-01-01

Campania

by Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
Published 2008-09-01

[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]

by Gianluca Furneri, Laura Santoni, Chiara Marchesi, Sergio Iannazzo, Paolo Angelo Cortesi, Achille Patrizio Caputi, Lorenzo Giovanni Mantovani
Published 2016-06-01

Farmaci orfani e malattie rare: un confronto internazionale delle normative di riferimento

by S. Martina, C. Denti, L. Garattini
Published 2001-09-01

Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey

by Massimiliano Povero, Lorenzo Pradelli, Paola Turco, Roberto Walter Dal Negro
Published 2014-06-01

Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy

by Francesco Mennini, Sergio Russo, Andrea Marcellusi
Published 2012-09-01

La day surgery centralizzata: l’appropriatezza clinica e organizzativa come leva di creazione di valore sanitario

by Bruno Vogliolo, Salvatore Nieddu, Maurizio Bianco
Published 2001-12-01

Ketorolac vs. morfina nel trattamento del dolore acuto in pazienti traumatizzati: un’analisi di minimizzazione dei costi

by G.L. Colombo, B. Borghi, M. Caruggi, A. De Nicola
Published 2001-06-01

Storia naturale dell’infiammazione allergica

by Maria Angela Tosca, Giorgio Ciprandi
Published 2002-12-01

Le valutazioni economiche in Italia: una revisione sistematica della letteratura esistente

by L. Garattini, R. Clemente, P. De Compadri, C. Denti
Published 2001-09-01

Analisi costo/efficacia della doxofillina vs. teofillina nella terapia dell’asma cronica reversibile dell’adulto

by Mario Eandi, Elisa Berno, Lorenzo Pradelli
Published 2002-06-01

Evaluation of health resources expenditure in two groups of psychotic patients treated with olanzapine and typical neuroleptics in a Italian Mental Health Department in Calabria Re...

by Anna Caputo, Luca Guidi, Giovanni Biricolti, Sergio Torchia
Published 2008-03-01

Pay-back direct to Regions: a new possibility for companies

by Orietta Zaniolo
Published 2007-03-01

Farmaci antipertensivi a confronto: costi e benefici per il paziente e la collettività

by Francesco Vittorio Costa
Published 2003-12-01

Tramadolo: profilo farmacologico, terapeutico e farmacoeconomico

by Loredana Serpe, Lorenzo Pradelli, Mario Eandi
Published 2004-09-01

Tiotropium bromide in the routine care of GOLD stage II COPD patients: a pharmaeconomic evaluation

by Orietta Zaniolo, Michela Carsi, Sergio Iannazzo
Published 2011-06-01

The discovery of “sale amarissimo antifebbrile” (“bitter febrifugal saline”) by Bartolommeo Rigatelli, i.e. the origins of pharmacoeconomics

by Piero Marson, Giampiero Pasero
Published 2008-03-01